Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
This clinical-stage biotech focused on GPCR-targeted therapies reported a notable insider sale amid rapid share price appreciation.
Overview
Daniel D. Long, SVP, Drug Discovery at Septerna (NASDAQ:SEPN), reported the exercise and immediate sale of 15,000 shares of Common Stock on June 22, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($35.51); post-transaction value based on June 22, 2026, market close.
Details
* 1-year performance calculated using June 27, 2026, as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.